Abstract: Presence and severity of cardiovascular calcifications strongly predict cardiovascular morbidity and mortality in patients with CKD. This multicenter, crosssectional study primarily aimed to determine prevalence of abdominal aortic calcification (AAC) detected by plain lateral abdominal radiograph, and secondarily aimed to assess predictive factors for AAC. Patients (N = 1500), aged 18-70 years, with CKD stages 3-5D for ≥3 months prior to evaluation, were enrolled at 24 study centers in Thailand; 54.3% were non-dialysis patients. The prevalence of AAC was 70.6% and 70.8% in non-dialysis and dialysis patients, respectively. Patient's advanced age and widening pulse pressure were identified as predictive factors for AAC ≥ 5 in non-dialysis patients, while patient's age, history of coronary heart disease or diabetes, longer dialysis vintage, and increasing corrected serum calcium or high-sensitivity C-reactive protein were identified as such in dialysis patients. With additional regression having covariates in binary, corrected serum calcium ≥9.5 mg/dL gave an OR 1.974 (95% CI: 1.324-2.943) for AAC ≥ 5 among the dialysis patients. AAC in diabetes subgroup (N = 692) was additionally evaluated and found that it was prevalent at 84.7% with increased phosphorus as predictive factor (OR, 1.178; 95% CI: 1.032-1.344) and 1,25 (OH) 2 vitamin D as protective factor (OR, 0.983; 95% CI,.The prevalence of AAC in the Thai CKD population is lower than that reported in the literature, and yet the burden is prominent in patients coexisting with diabetes. Variable relationships identified in this study may guide preventive measures against cardiovascular complications in CKD patients.
The Impact of Prevalence of Abdominal aortic Calcification of Thai Chronic Kidney Disease (IM-PACT-CKD) study is a multicenter, cross-sectional study aimed to determine the prevalence of abdominal aortic calcification (AAC) in Thai chronic kidney disease (CKD) patients with or without dialysis, which reflects the disease burden, and may guide therapeutic options. The study also identifies predictive factors for vascular calcification, which may assist in its prevention. Cardiovascular calcifications in patients with CKD are more prevalent, progressive, extensive, and severe, compared with the non-CKD population (1) , and the presence and severity of cardiovascular calcifications strongly predict cardiovascular morbidity and mortality in patients with CKD, (2) (3) (4) (5) (6) , even in those not undergoing dialysis (6) . Most studies examining calcification in CKD patients use computed tomographic (CT)-based techniques (7) to detect cardiovascular calcification; however, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for chronic kidney disease-mineral bone disorder (CKD-MBD) (7) suggest using lateral abdominal radiographs (8) , which are widely available, less costly than CT imaging, and provide acceptable sensitivity and specificity for both routine practice and clinical research purposes (9) to detect the presence or absence of vascular calcification in patients with CKD stage 3-5D. Indeed, lateral radiology of the lumbar aorta has been shown to correlate well with electron beam computerized tomography results (9) .
The AAC score is a grading system, for which localized calcifications at different parts of the abdominal aorta are quantified, allowing assessment of the severity and progression of calcification (8, (10) (11) (12) . Evaluation of vascular calcification is useful in real-life practice in providing physicians with information regarding cardiovascular risk stratification and therapeutic guidance. The KDIGO guidelines for CKD-MBD (7) suggest restricting the dose of calcium-based phosphate binders in the presence of arterial calcification in patients with CKD stages 3-5D and hyperphosphatemia. Data from patients receiving calcium-based phosphate binders consistently highlight the risk of inducing hypercalcemia and calcium overload, necessitating dose reduction (7) .
Data regarding vascular calcification in patients with CKD remains lacking in Thailand. This study would not only fill the data gap, but also shed light on covariate associations with AAC. Given that diabetes mellitus (DM) becomes an increasingly recognized population affected by vascular calcification, in particular when coexisting with CKD (13, 14) , prevalence data and other covariate analyses in this patient subgroup were therefore additionally explored in this study.
PATIENTS AND METHODS

Study design and patients
This was a multicenter, cross-sectional disease registry study, conducted over 18 months. The selected sites were hospitals with a nephrologist, a dialysis service (HD/ PD), X-ray facilities and a laboratory (in-house or outsourced). Patients were recruited using consecutive enrollment, and were included if they had confirmed CKD stage 3-5 with dialysis or non-dialysis for ≥3 months prior to evaluation, were aged 18-70 years, and had signed a data release consent form prior to study procedures; CKD and CKD stage were defined according to the 2003 K/DOQI Work Group definition (15) . Patients were excluded if they were post-renal transplant, pregnant, or not suitable for X-ray, had acute kidney injury, very severe comorbidities with poor survival outcome, concomitant diseases that may affect calcium status and soft tissue calcifications (sarcoidosis, multiple myeloma, HIV, or amyloidosis), or had undergone parathyroidectomy. The study protocol was conducted in accordance with the Declaration of Helsinki and approved by the local Ethics Committees at each study site.
Evaluation criteria
The primary endpoint was to determine the prevalence of AAC and the secondary endpoint was to determine predictive factors for AAC in Thai dialysis and non-dialysis CKD patients. Assessments included AAC scores stratified by the patient groups with dialysis versus non-dialysis, as well by CKD stage and DM status. Patient history, physical examination, and laboratory results were collected from medical records. Cardiovascular risk factors were defined as described by Menon et al. (16) . Laboratory results were derived from the latest record taken within the previous 3 months, except the intact parathyroid hormone (iPTH) result, which was taken within the previous 6 months. Total serum calcium level was corrected according to the albumin level: corrected serum calcium (mg/dL) = total calcium (mg/dL) + 0.8 × (4 − serum albumin (g/dL) (15) . Blood samples were taken within a week after enrollment and were assessed at a central laboratory for active vitamin D (1,25-(OH) 2 D) and high sensitivity C-reactive protein (hs-CRP), using commercialized ELISA kits from Immundiagnostik, Bensheim, Germany.
Lateral and anterior-posterior (AP) radiographs of the lumbosacral (LS) region were taken within 1 week following enrollment. Radiography was performed with the patient in a standing position using standard radiographic equipment. The digital images were evaluated centrally by two welltrained independent radiologists (readers) who were unaware of the clinical background of the patients. The calcification levels were quantified using the 24-point scoring method described by Kauppila et al. (8) . The final AAC score for a patient was an average of the scores from the two readers. If the scores from the two readers differed by ≥5 points, they reevaluated the film and used the average of the four readings for the final score.
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Statistical methodology
Primary analysis
Since the presence of calcification emergence is considered clinically meaningful, an AAC score of ≥1 was justified as the cut-off level for calculating AAC prevalence reported in the current study. This justification relied on patients with CKD 3-5D with known vascular calcification being considered at the highest cardiovascular risk (KDIGO 2009 
Secondary analysis
Predictive factors for an AAC score of ≥5 were first examined by means of univariate data analyses. A univariate P-value of <0.10 was justified for any independent variable being subject to multivariate logistic regression analysis. The identified predictive factors were described with odds ratio (OR) and 95% CI. A P-value of <0.05 was considered statistically significant. All statistical analyses were performed using SAS 9.4.
RESULTS
One thousand five hundred patients with CKD stages 3-5D, from 24 study centers covering the six geographical regions of Thailand, which represent the demographics of the Thai population were enrolled. Patients were classified according to their dialysis status (Fig. 1) . A total of 686/1500 (45.7%) patients were on renal replacement therapy and, of these patients, 432/686 (63.0%) were on maintenance hemodialysis.
Baseline characteristics by treatment status are shown in Table 1 . Approximately half of population was male. Median age was around 54-60 years. Patients undergoing dialysis, under this observation, were younger than those not on dialysis (54 versus 60 years, P < 0.0001). Diabetic nephropathy was the most common CKD etiology, accounting for 32.9%-44.7%. Approximately two-third of patients had at least three cardiovascular risk factors. Phosphate binders, mostly calcium-based binders, were more often used in patients undergoing dialysis (78.1%) than patients not on dialysis (29.0%). Laboratory data over CKD progression (i.e., through CKD3, 4, 5-ND, and 5-D) are shown in Table 2 . The results showed some trends of increasing phosphate, calcium-phosphorus (Ca×P) products, and iPTH, and decreasing vitamin D levels over CKD3 to 5-D.
Abdominal aortic calcification score
The intraclass correlation coefficient of the two readers was 0.9. Overall AAC prevalence as defined by a score of ≥1 was 70.7% (95% CI: 68.4-73.0%, Table 3 ). By treatment status, AAC was prevalent at 70.6% (95% CI: 67.4-73.7%) and at 70.8% (95% CI: 67.3-74.1%) for patients not on dialysis and patients undergoing dialysis, respectively. It should be noted that incremental calcification prevalence over CKD progression, which is supposed to be present according to pathological process point of view (i.e. the context of CKD-MBD (7)), was not observed as the prevalence appeared to be unchanged and remained stable around 70% throughout CKD3 to CKD5-D (CKD5 on dialysis). However, a marginal trend of increased prevalence was observed for a more severe calcification (i.e., AAC ≥ 5, as shown in Fig. 2 ; increasing from 27.0% in CKD3 to 35.1% in CKD5-D). It is possible that the lack of calcification prevalence progression was a phenomenon confounded by surrounding covariates existing in realworld data. In order to explore this notion, additional multiple logistic regression analysis was done. The results showed remarkable increases in odds ratio for the calcification (either with AAC ≥1 or AAC ≥5, Fig. 3A and B, respectively) at the late stage CKD, upon covariate adjustments being included into the model, having patients' age and/or diabetes status as the adjusted covariates. This result indicates that the patients' age, which had a strong association with AAC (data to be shown later in Table 4 The IMPACT-CKD Study 3 visibility, thus rendering the lack of prevalence progression as an illusion to the disease pathology point of view.
Analyses of predictive factors for AAC
Given that CKD patients with an AAC score ≥ 5 are at higher risk of mortality than those with AAC <5 (4), the analyses were carried out at this AAC cut-off point. The analyses between variables and respective AAC scores were firstly done by means of one-to-one relationship using univariate analyses (data not shown) and then interactions across variables were subsequently done with multivariate analysis, for which the results are shown in Table 4 . BUN, blood urea nitrogen; Ca, calcium; CKD, chronic kidney disease; HbA1C, glycosylated hemoglobin; HD, hemodialysis, HDL, high density cholesterol; hs-CRP, high-sensitivity C-reactive protein; iPTH, intact parathyroid hormone; LDL, low density cholesterol; P, phosphorus; SD, standard deviation. (16) . ACE-I, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; BMI, body mass index; HbA1C, glycosylated hemoglobin; HDL, high density cholesterol; HMG-Co A, 3-hydroxy-3-methylglutaryl-coenzyme A; hs-CRP, high-sensitivity C-reactive protein; iPTH, intact parathyroid hormone; LDL, low density cholesterol.
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Increasing age and widening pulse pressure (the difference between systolic and diastolic blood pressure) were identified as predictive factors for AAC in patients not on dialysis, while age, history of coronary heart disease or diabetes, longer dialysis vintage, and increasing corrected serum calcium or hs-CRP (both continuous variables) were predictive factors for patients with ongoing dialysis. In order to explore clinically meaningful information, a series of regression analysis models were performed with different corrected serum calcium cut-offs (Table 5 ). The results showed a peak OR of 1.974 (95% CI, 1.324 to 2.943) for the corrected serum calcium cut-off at 9.5 mg/dL. These analysis models were performed by fixing all other variables, except for the serum calcium, under the same conditions as for those shown in Table 4 . A similar analysis was applied to the hs-CRP data using a single cut-off of 1.0 mg/dL. The results showed no significant relationship between the categorical hs-CRP and AAC in this model (OR, 1.570 [95% CI, 0.995 to 2.475], P = 0.0524).
Diabetes subgroup analyses
In the study, 692 patients (46.1%) had diabetes mellitus (DM); therefore, a DM subgroup analysis was conducted. Of the patients with diabetes, 437 (63.1%) patients were CKD3-5-ND and the other 255 (36.9%) were CKD stage 5-D. The prevalence of AAC in the DM subgroup was significantly higher than in the non-DM subgroup and in the overall population, assessed either by an AAC cut-off of ≥1 (84.7% vs. 58.8% vs. 70.7%; P < 0.001) or an AAC cut-off ≥5 (42.1% vs. 21.2% vs. 30.8%; P < 0.001, respectively).
In the final step of the multiple regression (Table 6 ), increasing age, history of coronary artery disease, increasing serum phosphorus, and decreasing active vitamin D were found to be the potentiating factors for calcification in the DM subgroup.
DISCUSSION
The prevalence of 70.7% AAC (70.8% among dialysis patients) in current study was considered to be lower than that reported in a Caucasian population. Using the same calcification evaluation, Toussaint et al. reported 94.4% prevalence in Australian hemodialysis patients (mean age 69 years, maximal age 90 years) (17). Honkanen et al. as well reported a prevalence of 81% AAC in 933 dialysis patients (mean age 61.4 years) (10) . In another recent study of a Japanese cohort of 347 patients not on dialysis (mean age 67.4 ± 12.3 years), with a more advanced measurement method of noncontrast CT scan Tatami et al. (6) reported an AAC prevalence of 86.3%. Factors for these discrepancies in prevalence remain unknown, but are likely attributable to the difference in the study population's age and ethnicity. Another speculation is the dietary difference. WHO Food Cluster Diets (18) reports remarkable differences in milk-and processed food consumptions, which may contain different calcification-inducing and/or suppressing factors, among the Caucasian and Asian clusters. It can be worth discussing another noticeable point of the current data showing a significant sagging down of prevalence data among CKD5-ND (CKD5 not on dialysis) population. Figure 3 shows a series of small but increasing AAC prevalence (as of AAC ≥ 5) over CKD stages, in which the increasing prevalence was interrupted with such sagging down at CKD5-ND. Taking into consideration the knowledge from other epidemiological data; i.e. a significant portion The IMPACT-CKD Study 5
of CKD patients usually die early before entering ESRD (19) to which cardiovascular cause is mainly accountable for (20), we may anticipate an existence of high CV mortality in the real-world among Thai CKD5-ND, where the mortality had taken patients with high AAC away from our observation, thus appearing to us as the sagging down in prevalence. Indeed, the study protocol excluded patients anticipated with poor survival, and thus the exclusion became a selection bias enhancing the appearance of this figure. With all regards, the anticipated AAC prevalence carrying forward should have been higher than what we are reporting now, if some CKD5-ND patients were not prematurely excluded and could survive toward CKD5-D.
The lack of observable progression in calcification prevalence over CKD stages has been analyzed and discussed in the Results Section. The patient's age covariate was shown to conceal figures of calcification progression from the observable prevalence (Fig. 3) . Under real practice as with clinical reasons, younger patients are more likely accessible to dialysis treatments than the elderly, which might let the ongoing dialysis group be younger. It should be noted in addition that the trend of calcification progression became more evident when the AAC score cut-off of ≥5 was used; thus, adopting the calcification prevalence data using an AAC cut-off of ≥5 may be warranted for general reference.
The secondary analysis was to identify factors predictive of AAC. Most factors identified in the study have already been known, for example, age, pulse Except corrected serum calcium, which was set to categorical type with different cut-offs for each round of regression, parameters of the other variables were set at the same setting (1, 10, 21) . Increased calcification as a function of time, either by age or dialysis vintage, has been documented in several studies (1, (22) (23) (24) (25) (26) . In our study, increased age was the most significant identifiable predictive factor (P < 0.0001), with ORs of 1.115 and 1.083 for every year of increasing age, respectively, for both patient groups. Indeed, an overall correlation coefficient as high as 0.365 (P < 0.0001) was found between the age and AAC scores.
One of the most striking findings, corrected serum calcium was identified as a significant predictor of AAC in patients on dialysis (as a continuous variable: OR, 1.468; 95% CI, 1.163 to 1.852; P = 0.0012). Clinical evidence to date has not much associated serum calcium and calcification in CKD patients; Raggi et al. (24) reported a non-significant trend for increased carotid artery calcification in adult hemodialysis patients with higher serum calcium. Nevertheless, similar associations have been found in some non-CKD contexts, for example, Rubin et al. (27) described a relationship between serum calcium and increased carotid plaque thickness in a general population cohort (N = 1194). In another study, Bolland et al., (28) The corrected serum calcium was also set as a categorical variable in the study as an additional regression model, which showed a peak OR of 1.974 (95% CI, 1.324 to 2.943; P = 0.0008) at the cut-off of 9.5 mg/dL. In COSMOS, a 3-year, prospective observational study of CKD-MBD conducted in 4500 CKD5 adult hemodialysis patients from 20 European countries, the serum calcium cut-off of 9.5 mg/dL was also used (30) . COSMOS assessed mortality as the outcome of interest and identified the U-curve effect of serum calcium on mortality. Interestingly, their corrected serum calcium cut-off of 9.5 mg/dL was the earliest point at which the hazard ratio became significant, which is consistent with our findings. From the evidence provided here, the current study would be the first evidence to demonstrate the influence of serum calcium below the hypercalcemic range on increased aortic calcification in CKD patients on dialysis. It has been postulated that increased extracellular calcium potentiates calcification, in other words, matrix mineralization, in which calcium stimulates Pit-1 Na-P channel synthesis, resulting in enhanced phosphorus uptake and subsequent matrix production by vascular smooth muscle cells and a thermodynamic mechanism via increased Ca×P product (31) . Another identifiable predictor is hs-CRP, which has a known role as a sensitive marker of systemic inflammation in calcification (26) .
Diabetes has long been known for its association with arteriosclerotic disorder presenting with calcification, so called Mönckeberg's arteriosclerosis (32) . Significant higher AAC prevalence in DM sub-group in current study, as compared with non-DM counterpart (84.7% vs. 58.8%), strongly supports this notion far advancing into CKD population. In accordance, a number of published reports have documented vascular calcification percentage within a range of 54%-93% among DM patients versus 25%-54% among non-DM counterparts who were either at early-(33) or late-stage CKD (34) . Given the remarkable association in terms of high calcification prevalence ascertained here, with higher calcification progression (35) , and with higher mortality rate (36), our identification in this DM-subgroup of predictive factors, in particular the modifiable ones such as increased serum phosphorus (OR 1.178, P = 0.0153) and decreased active vitamin D (OR 0.983, P = 0.0104), calls attention for a more aggressive measure to improve outcomes in this patient group by focusing on these factors. The role of phosphorus is quite straightforward for pathological mechanisms (7) and further implications, however the role of vitamin D is still debatable as the association between vitamin D disorders and vascular calcification seems to be U-shaped in general CKD; i.e., if it is too low, it mediates pro-inflammation to which calcification is indirectly enhanced, as well as too high, whereby it directly promotes the calcification (37). Our finding, which is focusing specifically on CKD patients with DM, is reflection that the pro-inflammation led by vitamin D depletion is outweighed in pathological mechanisms in this group. In relevance to this notion, Schiller et al. (36) recently showed that patients with cholecalciferol deficiency had a significantly higher mortality than those with normal levels, among DM patients undergoing dialysis. It should be emphasized from our data that proportions of patients with low 1,25-(OH) 2 D were obviously high even early in CKD3 and throughout CKD stage (16.7% for CKD3, 22.9% for CKD4, 58.8% for CKD5-ND, and 71.1% for CKD5-D, according to normal reference 17-65 pg/mL in persons aged ≤60 years, and 10-15 pg/mL in persons aged >61 years). Taking these matters together, a good phosphorus control and a low dose vitamin D supplementation may be
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warranted for future research to determine whether they can help improvement in disease outcomes in this population. This study also provided some demographic characteristics representing current practices in CKD management in Thailand. This particularly relates to the numbers of patients who remain outside the standard laboratory values, for example, a large portion of patients did not achieve hemoglobin, albumin, lipid, and phosphorus control, a proper dialysis session, or proper dialysate components, all of which require further improvements.
A limitation of this epidemiologic survey is its cross-sectional design, for which the causal relationship between factors and outcomes is not easy to establish; however, its strength is in its primary objective and a relatively large number of patients from consecutive enrollments from multiple centers nationwide, which represent the demographics of the Thai population. Our analyses and discussions also have attempted to understand disease pathology occurring in a real-world context from this epidemiological data.
CONCLUSION
We have reported the abdominal aortic calcification prevalence data in Thailand and demonstrated some of the variables in predictive factors that may pave the way towards preventive measures to improve cardiovascular outcomes in patients with CKD and in patients with dual problems of DM and CKD.
